spacer
home > > spring 2009 > ediary time
PUBLICATIONS


eDiary Time

Back in the days of pen and paper clinical trials monitoring, something familiar but disconcerting caught my attention as I got out of the car. There in the next car sat a patient busy filling in his diary card with peak expiratory flow (PEF) readings and symptoms for the past month. Mentioning this to the investigating consultant, he called the patient in, commended him for having a complete diary, and then as he rubbed his finger over it, said, “oh dear the ink is still wet!” Having observed this, I concluded that there had to be a better way of recording diary data. The answer came in the early 1990s with the development of e-spirometric diaries. Chowienczyk et al compared paper versus electronic recording of spirometry data, demonstrating that 33 per cent of completed entries were either invented, mistimed or misread, and were often retrospectively entered (1). Since then, other studies have confirmed that paper diaries often contain invented data (2,3).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer

Initially qualifying as an entomologist, Aleck Harrison swiftly moved from ‘bugs to drugs’ and spent 34 years with Boehringer Ingelheim Ltd. Evolving from CRA to managing international respiratory studies, he advised a number of companies on spirometric diary development. Having semiretired, he started the consultancy of AJH Partners (Contract Research and Consultancy). Amongst his recent activities, he has supported respiratory companies, including Vitalograph Ltd, with the introduction and development of their centralised spirometry system.

spacer
Aleck Harrison
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

ERT Acquires APDM Wearable Technologies to Reinvent Endpoint Measurement in Clinical Trials

ERT, the global leader in clinical endpoints data collection, today announced the acquisition of APDM Wearable Technologies (APDM, Inc.), a next-generation provider of wearables and digital biomarkers. The combined company will generate higher-fidelity and more powerful data to enable clinical trials to be more predictable, cost-effective, and efficient. Thereby, reinventing endpoint measurement.
More info >>

White Papers

Is Your Biobank Ready for the Challenge of Biomarker-based Research?

BioFortis

Targeted and personalized studies with well-defined patient segmentation biomarkers are becoming the norm in clinical trials. This increased interest in molecular biomarker studies necessitates a rigor and sophistication in sample management within the clinical trial context that is often not supported either by traditional clinical trial management software (CTMS), or biobanking systems.  Download our Next Generation Biobanking whitepaper and learn about how to overcome the key challenges in clinical trial sample management from working in a distributed network of partners and stakeholder to managing consents and generating scientific insights.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement